©The Author(s) 2024.
World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3905-3912
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3905
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3905
Table 1 Baseline characteristics of the patients (n = 60), n (%)
| Characteristics | Value |
| Median age, years (range) | 58 (35-75) |
| Sex | |
| Male | 36 (60) |
| Female | 24 (40) |
| ECOG performance status | |
| 0 | 42 (70) |
| 1 | 18 (30) |
| Metastatic sites | |
| Liver | 28 (47) |
| Peritoneum | 24 (40) |
| Lymph nodes | 20 (33) |
| Lung | 12 (20) |
| Bone | 8 (13) |
| HER2 status | |
| IHC 3+ | 48 (80) |
| IHC 2+/FISH+ | 12 (20) |
- Citation: Zheng CW, Yang YM, Yang H. Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer. World J Gastrointest Oncol 2024; 16(9): 3905-3912
- URL: https://www.wjgnet.com/1948-5204/full/v16/i9/3905.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i9.3905